Aura Biosciences Inc. (AURA)
NASDAQ: AURA
· Real-Time Price · USD
5.92
-0.02 (-0.34%)
At close: May 23, 2025, 3:59 PM
5.91
-0.17%
After-hours: May 23, 2025, 04:08 PM EDT
Company Description
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer.
The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology.
It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.
It also develops AU-011 in additional ocular oncology indications, including choroidal metastases.
The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Aura Biosciences Inc.

Country | United States |
IPO Date | Oct 29, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 106 |
CEO | Dr. Elisabet de los Pinos Ph.D. |
Contact Details
Address: 85 Bolton Street Boston, Massachusetts United States | |
Website | https://www.aurabiosciences.com |
Stock Details
Ticker Symbol | AURA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001501796 |
CUSIP Number | 05153U107 |
ISIN Number | US05153U1079 |
Employer ID | 32-0271970 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Elisabet de los Pinos Ph.D. | Founder, Chief Executive Officer, President & Director |
Amy Elazzouzi | Interim Chief Financial Officer, Interim Principal Accounting Officer, Senior Vice President of Finance & Treasurer |
Conor Kilroy | Chief Legal Officer & Secretary |
Dr. Mark Plavsic D.V.M., Ph.D. | Chief Technology Officer |
Dr. Anthony Daniels M.D. | Vice President & Therapeutic Area of Head Ocular Oncology |
Dr. Jill J. Hopkins M.D. | Chief Medical Officer & President of Research and Development |
Dr. Richard Mountfield Ph.D. | Senior Vice President of Regulatory Affairs & Quality |
Dr. Sabine Brookman-May | Senior Vice President & Therapeutic Area Head of Urologic Oncology |
Patrick Nealon | Senior Vice President of Clinical Development Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 20, 2025 | 4 | Filing |
May 20, 2025 | 4 | Filing |
May 19, 2025 | SCHEDULE 13D/A | [Amend] Filing |
May 16, 2025 | 3 | Filing |
May 16, 2025 | 8-K | Current Report |
May 16, 2025 | 424B5 | Filing |
May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
May 15, 2025 | 424B5 | Filing |
May 15, 2025 | 10-Q | Quarterly Report |
May 15, 2025 | 8-K | Current Report |